Discover the Evexia advantage Start ordering today
Take advantage of all the time and money-saving features that Evexia Diagnostics has to offer. Simply click the button below to get started.
Register Now86704; 86706; 86708
Overview:
Use: To access patients for immunity to Hepatitis A Virus (HAV) and Hepatitis B Virus (HBV). Detectable total anti-HAV antibody indicates immunity to HAV infection. Although usually not sensitive enough to detect the low level of protective antibody after vaccination, anti-HAV tests also might be positive after hepatitis A vaccination. The detection of anti-HBs antibodies in the absence of anti-HBc antibodies indicates immunity to HBV infection due to vaccination. The detection of both anti-HBs and anti-HBc antibodies indicates immunity due to natural infection.
Limitations: The assays in this panel have not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, coed blood, or patients less than 2 years of age.
Methodology: Immunochemiluminometric assay (ICMA)
Collection Instructions:
Specimen: Serum or EDTA plasma
Volume: 2.5 mL
Minimum Volume: 1 mL (Note: This volume does not allow for repeat testing.)
Container: Gel-barrier tube, red-top tube, lavender-top (EDTA) tube, plastic transport tube
Collection: If tube other than a gel-barrier tube is used, transfer separated serum/plasma to a labelled plastic transport tube. Do not freeze gel-barrier tube (pour off serum first).
Storage Instructions: Room temperature
Causes for Rejection: Heat-inactivated specimens; cord blood; cadaveric specimens; or body fluids other than serum or EDTA plasma; gross hemolysis; excessive lipemia; improper labeling
Take advantage of all the time and money-saving features that Evexia Diagnostics has to offer. Simply click the button below to get started.
Register Now